TY - JOUR T1 - Prospective multicentre study of experience in real-world clinical practice in monitoring reported outcome measures (PROMs) of patient with a diagnosis of psoriatic and/or spondyloarthritis and initiating treatment with secukinumab JO - Reumatología Clínica (English Edition) T2 - AU - Garrido,Juan José Lerma AU - Pérez,Antonio Gracia AU - Torres,Antonio Pérez AU - Cid,Amalia Rueda AU - Almela,Clara Molina AU - Cubillo,María Dolores Pastor AU - Fernández,Cristina Campos AU - Trull,Isabel Balaguer AU - Carmona,Loreto AU - Catalá,Javier Calvo SN - 21735743 M3 - 10.1016/j.reumae.2020.07.010 DO - 10.1016/j.reumae.2020.07.010 UR - https://reumatologiaclinica.org/en-prospective-multicentre-study-experience-in-articulo-S2173574321000721 AB - ObjectiveTo analyse the effect of secukinumab on self-reported variables of patients diagnosed with psoriatic arthritis and/or ankylosing spondylitis in relation to their health status, pain, fatigue, sleep and quality of life. MethodsA six-month, observational, longitudinal, prospective, multicentre study was conducted with 39 patients who initiated treatment with secukinumab as therapy for psoriatic arthritis and/or spondylitis. The main variables were changes in patient-reported measures and they were evaluated by means of the questionnaires: FACIT-fatigue, Insomnia Severity Index, EuroQol-3L-5D and PsAQoL. In addition, depending on the type of disease (peripheral psoriasis or spondyloarthritis) the DAS28 with ESR or the BASDAI were calculated, respectively. ResultsLevels of fatigue, moderate and severe insomnia significantly reduced after 6 months of treatment with secukinumab. At the same time, patient-reported quality of life increased significantly (P = .006). Data on pain and discomfort also show significant improvement after the treatment. ConclusionsPatients with psoriatic arthritis and/or ankylosing spondylitis who start treatment with secukinumab show improvement at 6 months in all effect sizes of the treatment, particularly in sleep, fatigue and quality of life. Furthermore, patient-reported outcome measures are of additional clinical value and allow more accurate and closer assessment of their real status of health and well-being. ER -